Conjunctivitis News and Research

RSS
Conjunctivitis is an eye infection that may cause redness and discharge from the eye, sometimes with pain or itching. It can be caused by bacteria or viruses.
Phase 3 clinical trial results of Inspire Pharmaceuticals' PROLACRIA announced

Phase 3 clinical trial results of Inspire Pharmaceuticals' PROLACRIA announced

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts

Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts

Roche launches new automated clinical laboratory system for HPV and CT/NG tests

Roche launches new automated clinical laboratory system for HPV and CT/NG tests

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

NanoViricides announces filing of its quarterly report with the SEC

NanoViricides announces filing of its quarterly report with the SEC

Tibotec Therapeutics'  INTELENCE granted FDA traditional approval

Tibotec Therapeutics' INTELENCE granted FDA traditional approval

Treatment of allergic rhinitis can improve nasal and ocular symptoms

Treatment of allergic rhinitis can improve nasal and ocular symptoms

ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies

ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Patient enrollment in three late-stage clinical trials completed

Patient enrollment in three late-stage clinical trials completed

Financial results for third-quarter 2009 announced by Combinatorx

Financial results for third-quarter 2009 announced by Combinatorx

sanofi-aventis reports financial results for the third quarter of 2009

sanofi-aventis reports financial results for the third quarter of 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

Anti-viral drug development programs progress successfully, reports NanoViricides

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

ISTA Pharmaceuticals' presentations on Phase 3 clinical results of Bepreve

ISTA Pharmaceuticals' presentations on Phase 3 clinical results of Bepreve

Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC

Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC

Prednisporin is a key asset in the proposed acquisition of Fovea by Sanofi-Aventis

Prednisporin is a key asset in the proposed acquisition of Fovea by Sanofi-Aventis

Preliminary Phase 2 study results of Plicera drug released

Preliminary Phase 2 study results of Plicera drug released

Fovea Pharmaceuticals to sell 100% of its share to Sanofi-Aventis

Fovea Pharmaceuticals to sell 100% of its share to Sanofi-Aventis